May 7: The Week in Cancer News
A Food and Drug Administration panel recommends withdrawing approvals for two treatment indications for immunotherapy drugs, and more news of the week from Cancer Today.
Progress Against Cancer
A Food and Drug Administration panel recommends withdrawing approvals for two treatment indications for immunotherapy drugs, and more news of the week from Cancer Today.
Many patients facing a cancer diagnosis ask their doctors a simple question: “What should I eat?” That elemental question has perplexed scientists for centuries. In a stirring discussion during the Opening Plenary session of...
President Biden resurfaces a proposal for a new health care agency, and more news of the week from Cancer Today.
Scientists discussed the mechanisms of chemotherapy-related cognitive impairment at a session dedicated to symptom science at the AACR Annual Meeting 2021.
Immunotherapy has revolutionized cancer treatment over the past decade, providing potentially lifesaving therapies to many patients who otherwise would have limited options. Despite its success for many patients, immunotherapy still has challenges to overcome. Fortunately, novel strategies to improve the efficacy...
The immune systems of people with blood cancer respond differently to the coronavirus than the immune systems of people without cancer.
A study indicates that people are delaying medical care until they are eligible for Medicare, and more news of the week from Cancer Today.
Underrepresentation of members of minority groups in public genomic databases could lead to misleading test results, and more news of the week from Cancer Today.
A study indicates breast cancer centers often recommend earlier and more frequent screening than national guidelines, and more news of the week from Cancer Today.
With the August 2020 U.S. Food and Drug Administration approvals of the Guardant 360 CDx and FoundationOne Liquid CDx liquid biopsy tests to detect genetic abnormalities over multiple tumor types, the use of liquid...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More